Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€246.00

€246.00

-0.060%
-0.15
-0.060%
€254.92
 
04.10.24 / Tradegate WKN: 866197 / Symbol: DHR / Name: Danaher / Stock / Machinery, Equipment & Components / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Danaher Corp. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Danaher

sharewise wants to provide you with the best news and tools for Danaher, so we directly link to the best financial data sources.

News

Here's Why Shares in This Hot Healthcare Stock Surged This Week: https://g.foolcdn.com/editorial/images/785683/monoclonal-antibody-stocks-to-buy.jpg
Here's Why Shares in This Hot Healthcare Stock Surged This Week

The bioprocessing market is about to recover. That's the conclusion from Repligen's (NASDAQ: RGEN) second-quarter earnings report released earlier in the week and the reason for the stock's 17.7%

Here's Why Danaher Stock Surged Today: https://g.foolcdn.com/editorial/images/784266/life-sciences-stocks-to-buy-best-medical-stocks.jpg
Here's Why Danaher Stock Surged Today

Danaher's (NYSE: DHR) core revenue decline of 3.5% in the second quarter might not seem like anything to write home about. Still, as ever in investing, it's about context, and the company's earnings